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Background: Interleukin-33 (IL-33) has been linked to chronic heart failure (CHF) in animal studies, but data on
serum IL-33 levels in human CHF are not available. We analyzed levels of IL-33 in serum, and investigated the
possible role of IL-33 in oxidative stress.
Methods: A total of 191 subjects with advanced systolic CHF (CHF group), 175 patients with pre-existing cardiac
diseases but no CHF (non-CHF group), and 177 healthy controls (HC group) were enrolled. Serum levels of IL-33,
soluble ST2 (sST2) and N-terminal-pro-brain natriuretic peptide (NT-proBNP), malondialdehyde (MDA) content,
erythrocyte superoxide dismutase (eSOD) activity, as well as left ventricular ejection fraction (LVEF), were
determined. The exact form of IL-33 in serum was identified. Effects of IL-33 and sST2 on MDA content and SOD
activity in angiotensin (Ang II)-stimulated AC16 cells were assessed.
Results: Serum levels of IL-33 and sST2 were elevated in CHF patients, whereas IL-33/sST2 ratios were decreased.
In CHF patients, pre-existing cardiac diseases and medications used upon hospital admission did not affect IL-33
concentrations or the IL-33/sST2 ratio. Full-length IL-33, which could not be detected in serum from HC and barely
detected in non-CHF patients, was significantly up-regulated in CHF patients. IL-33 levels were positively correlated
with markers of CHF severity. IL-33/sST2 ratios were slightly and negatively related to MDA concentrations. IL-33
directly reduced MDA and enhanced SOD activity in Ang II-stimulated AC16 cells, which were greatly attenuated by
sST2.
Conclusions: Serum levels of IL-33, especially the full-length form, were elevated in CHF patients whereas IL-33
bioactivity was reduced. In advanced CHF, IL-33 may exert anti-oxidation effects, which may be overwhelmed by
concurrently elevated levels of sST2.
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Despite advances in treatment, chronic heart failure
(CHF) remains one of the most important life-
threatening cardiovascular conditions. It is associated
with a high incidence in many western countries, poor
outcome, and considerable healthcare costs [1,2]. CHF is
a state of chronic deterioration in health with enhanced* Correspondence: dr.jingfengwang@gmail.com
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reproduction in any medium, provided the oroxidative stress [3]. Positive correlations between
increased levels of oxidative stress and CHF severity
have been reported [3]. Moreover, therapy involving
inhibitors of oxidation benefits CHF patients [4].
Interleukin (IL)-33 is an IL-1 superfamily cytokine [5,6].
It is the unique endogenous ligand for ST2 with soluble
(sST2) and transmembrane (ST2L) isoforms, which are
encoded by the same gene but regulated by different pro-
moters, and which produce different messenger ribo-
nucleic acid molecules (mRNAs) [7]. ST2L mediates the
effects of IL-33 whereas sST2 limits the activity of IL-33
[8]. Alterations in the serum levels of sST2 in CHF haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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results from these large clinical trials have consistently
shown that sST2 levels are elevated in CHF patients.
Moreover, sST2 levels correlated with plasma concentra-
tions of brain natriuretic peptide (BNP) and predicted ad-
verse outcomes [9,10]. In contrast to many IL-1
superfamily cytokines (e.g., IL-1β and IL-18) which can
have negative roles in cardiac diseases and ventricular re-
modeling [11], IL-33 has been demonstrated to have a po-
tent protective role in various experimental CHF studies
through inhibition of the nuclear factor kappa B (NF-κB)
cascade and reduction of oxidative stress [8,12].
IL-33 expression is significantly up-regulated by mech-
anical strain in cardiomyocytes and cardiac fibroblasts
[8]. Ventricular wall stress and mechanical load on ven-
tricular muscle fibers is substantially increased in CHF
patients, especially in those with end-stage CHF. Hence,
we hypothesized that IL-33 levels may be increased in
patients with advanced CHF and may play a part in the
regulation of oxidative response in these patients. Given
the important role of sST2 in CHF and IL-33 bioactivity,
we determined sST2 levels and explored their interac-
tions with IL-33, and in relation to oxidative stress.
Methods
The study protocol was approved by the Ethics Commit-
tee of Sun Yat-sen Memorial Hospital (affiliated to Sun
Yat-sen University, Guangzhou, China). Written
informed consent was obtained from each participant or
his/her relative/carer.
Study population
One hundred and ninety-one consecutive patients with
advanced systolic CHF (CHF group) admitted to Sun
Yat-sen Memorial Hospital and the First Affiliated Hos-
pital of Guangxi Medical University (Nanning, China)
from 2009 to 2011 were included. CHF was diagnosed
based on a history of cardiac diseases, symptoms and
signs of cardiac diseases, echocardiographic results, and
plasma levels of N-terminal-pro-brain natriuretic peptide
(NT-proBNP) according to established criteria [13,14].
Major exclusion criteria were: (i) CHF with preserved
left ventricular ejection fraction (LVEF ≥40%); (ii) acute
heart failure, acute myocardial infarction and myocardi-
tis; (ii) known current or past allergic diseases (e.g.,
asthma), autoimmune diseases (e.g., systemic lupus ery-
thematous), inflammatory diseases (e.g., rheumatic arth-
ritis and inflammatory bowel disease), or malignant
diseases. One hundred and seventy-five age- and sex-
matched patients with similar pre-existing cardiac dis-
eases but without CHF (non-CHF group) were admitted
in the same period and on the same hospital wards. In
addition, age-, sex- and ethnicity matched healthy indivi-
duals were used as healthy controls (HC group). Allparticipants were from the Chinese Han population.
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) recommendations were used in
the development of the population study [15].
Culture and stimulation of cells
To evaluate the anti-oxidative effects of IL-33 in human
cardiomyocytes, we assessed malondialdehyde (MDA)
contents and superoxide dismutase (SOD) activity in
angiotensin II (Ang II)-stimulated AC16 cells (ATCC,
Bethesda, MD, USA), a cell line derived from the primary
cultures of adult ventricular cardiomyocytes [16]. Cells
were maintained and grown as described previously [16].
Briefly, cells were plated in a six-well plate at 0.3 × 106/ml
and incubated in Dulbecco’s modified Eagle’s medium nu-
trient mixture F-12 (DMEM-F12; Invitrogen, Carlsbad,
CA, USA) with 1% penicillin (Invitrogen), 1% strepto-
mycin (Invitrogen), and 12.5% FBS (Invitrogen) at 37°C
and an atmosphere of 5% CO2 for 12 h. AC16 cells were
stimulated with Ang II (10 nmol/L, Sigma-Aldrich, St.
Louis, MO, USA) for 24 h in the presence or absence of
recombinant human IL-33 (1 ng/ml, 5 ng/ml, 10 ng/ml,
and 100 ng/ml; Sino Biological, Beijing, China) and sST2
(10 μg/ml; Sino Biological, Beijing, China).
Biochemical measurements
Blood samples were obtained from all subjects by
venipuncture upon hospital admission and collected in
sterile non-treated tubes. Serum was obtained by centri-
fugation (2000 rpm for 5 min), immediately frozen, and
stored at −80°C until subsequent batched analyses. Con-
centrations of IL-33 and sST2 in serum were analyzed
using commercially available enzyme-linked immuno-
assay (ELISA) kits (IL-33: Enzo, Farmingdale, New York,
USA; sST2: Medical & Biological Laboratories, Naka-Ku,
Nagoya, Japan). Given the possible role of sST2 in limit-
ing IL-33 activity, we calculated the ratio of IL-33 to
sST2 to approximately evaluate the possible bioactivity
of circulating IL-33 [17]. MDA contents were deter-
mined using an established and commercially available
method (Beyotime, Nantong, China) [18,19]. For assess-
ment of the level of erythrocyte superoxide dismutase
(eSOD), erythrocytes were lysed and eSOD activities
were determined using commercial kits (Beyotime).
Blood samples for the assessment of NT-proBNP levels
were kept in ethylenediamine tetra-acetic acid (EDTA)
tubes at room temperature and measured by electroche-
miluminescence immunoassay using a Roche ElecsysW
system (Roche, Basel, Switzerland).
It is well known that IL-33 can circulate in two forms:
full length and cleaved. IL-33 concentrations in serum
were too low to be detected directly by western blotting,
so we undertook immunoprecipitation analyses followed
by western blotting as described previously to identify the
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precipitated with mIL-33 antibody (1:100 dilution; Enzo).
Protein A agarose beads were added to collect the IL-33-
mIL-33 antibody complex. For western blotting, samples
were analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and blotted onto polyvi-
nylidene fluoride (PVDF) membranes (Millipore, Bedford,
MA, USA). Membranes were blocked and incubated with
primary antibody (mIL-33 antibody at 1:1000 dilution;
Enzo) and then secondary antibody (horseradish peroxid-
ase (HRP)-conjugated anti-mouse IgG at 1:10,000 dilution;
Jackson Laboratory, Bar Harbor, ME, USA). Visualization
of immunoreactive human IL-33 was undertaken using
enhanced electrochemiluminescence (ECL) reagents
(Thermo Fisher Scientific, Rockford, IL, USA).
For determinations of MDA levels and SOD activity in
AC16 cells, cells were lysed and supernatants collected.
MDA contents and SOD activity were measured using
the commercial kits described above.
Statistical analyses
Normally distributed continuous data are expressed as
mean ± SD or mean ± SEM (for MDA content and SOD
activity in AC16 cells), otherwise as quartiles (first, me-
dian, and third). Categorical variables are presented as
absolute and relative frequencies. Statistical comparisons
across groups were made using Pearson’s χ2 test for cat-
egorical variables and the t-test (or one-way ANOVA
followed by the Student-Newman-Keuls test for multiple
post-hoc comparisons if three or more groups were com-
pared) was used for normally distributed data. For non-
normally distributed data, the Mann–Whitney test was
used for two groups and the Kruskal-Wallis with Dunn’s
post-hoc test was adopted for more groups. To test
whether the statistical difference of IL-33 between the
CHF group and non-CHF group was significant with the
potential confounding factors under consideration, we
used logistic regression to calculate the adjusted the P
values for IL-33 and the IL-33/sST2 ratio between the
two groups (responsive variables: CHF group or non-
CHF group; explanatory variables: IL-33 or IL-33/sST2
ratio, age, heart rate, blood pressure, pre-existing cardiac
diseases, medications, and serum creatinine levels).
Spearman’s correlation coefficients were used to assess
the correlations between IL-33 (or IL-33/sST2 ratios)
and other continuous variables. All analyses were done
using SigmaPlot ver11.0 (SPSS, Chicago, IL, USA) and
statistical charts were made using OriginPro ver8.0 (Ori-
ginLab, Boston, MA, USA).
Results
Clinical characteristics
Table 1 lists the baseline characteristics of the subjects.
Age and sex profiles were not significantly differentamong the three groups. Patients were in New York
Heart Association (NYHA) class III (78 cases, 40.84%)
or class IV (113 cases, 59.16%). As expected, echocardio-
graphic abnormalities (reduced LVEF and increased size
of the left ventricle) were found in all CHF patients,
whereas these parameters were essentially normal in
non-CHF patients and controls. Levels of NT-proBNP,
creatinine and markers of oxidative stress were signifi-
cantly higher in CHF patients. The prevalence of various
pre-existing cardiac diseases was similar in non-CHF
and CHF patients; the predominant disease was coron-
ary heart disease, followed by hypertension, a concur-
rence of the two diseases, and cardiomyopathy.
Serum levels of IL-33 and sST2, and the IL-33/sST2 ratio
Serum levels of IL-33 and sST2 upon hospital admission
were determined and compared among the three groups.
Serum levels of IL-33 in the CHF group were signifi-
cantly higher than those in non-CHF patients and
healthy controls (Figure 1A). A similar trend was
observed for the serum levels of sST2 (Figure 1B). Inter-
estingly, despite elevated IL-33 concentrations, CHF
patients showed significantly lower ratios of IL-33/sST2
compared with non-CHF patients and healthy controls
(Figure 1C).
Some factors may affect IL-33 levels, so we used logis-
tic regression analyses to calculate the P values of IL-33
and IL-33/sST2 ratio adjusted by age, heart rate, blood
pressure, pre-existing cardiac diseases, medications, and
serum creatinine levels. Serum IL-33 levels remained
higher and IL-33/sST2 ratios remained lower after
adjustments (for IL-33: P< 0.01; for IL-33/sST2 ratio:
P< 0.01).
To explore the potential correlations between IL-33
levels and CHF markers of severity, we performed Spear-
man’s correlation analyses to assess the relationships
among IL-33 and NT-proBNP and LVEF. Results
revealed a positive correlation between serum levels of
IL-33 and NT-proBNP (Figure 2A) and a negative rela-
tionship between IL-33 concentrations and LVEF
(Figure 2B).
IL-33 forms
To identify the exact form of IL-33 in serum, we under-
took immunoprecipitation and western blotting analyses.
The full-length and cleaved form of IL-33 could be
detected in CHF patients, whereas only the cleaved form
was found in healthy controls. Full-length IL-33 was
barely detected in non-CHF patients (Figure 3). We
adopted all available methods to increase the sensitivity,
but visual bands could be observed only in 15 CHF
patients, 7 non-CHF patients, and 5 healthy controls.
The limit of detection for immunoprecipitation and
western blotting was 1.2-3 ng of total IL-33. These
Table 1 Characteristics of all participants
HC non-CHF CHF P*
n = 177 n= 175 n= 191
Age (years) 66.72 ± 5.73 66.98 ± 6.32 66.35 ± 5.91 0.60
Male (%) 102 (57.62%) 101 (57.71%) 109 (57.07%) 0.99
HR (beat/min) 78.46 ± 11.22 81.30 ± 14.58 72.17 ± 16.94 <0.01
SBP (mmHg) 115.10 ± 14.97 136.98 ± 29.04 127.74 ± 23.46 <0.01
DBP (mmHg) 71.97 ± 9.48 76.34 ± 11.96 71.01 ± 15.90 <0.01
Echocardiographic parameters
LVEF (%) NR 68.12 ± 7.14 27. 90 ± 4.09 <0.01
LVEDD (mm) NR 47.60 ± 3.44 59.07 ± 5.82 <0.01
LVESD (mm) NR 29.04 ± 3.16 37.88 ± 4.14 <0.01
Primary cardiac diseases
CHD (%) NR 103 (58.86) 103 (53.93) <0.01
HBP (%) NR 41 (23.43) 39 (20.42)
CHD+HBP (%) NR 31 (17.71) 35 (18.32)
DCM (%) NR 0 (0) 14 (7.33)
Chemical markers
serum creatinine (μmol/) NR 73.48 ± 5.04 130.58 ± 84.50 <0.01
NT-proBNP (ρg/ml) NR 88.89 (7.14-311.89) 5492.06 (187.21-18199.75) <0.01
eSOD (U/mg Hb) NR 1.41 ± 0.77 2.27 ± 1.11 <0.01
MDA (nmol/l) NR 4.11 ± 1.25 4.69 ± 1.97 <0.01
Continuous data are the mean ± SD or median and range (for NT-proBNP). Categorical variables are presented as absolute and relative frequencies.
*, For categorical data, P values were derived by Pearson’s χ2 test; for continuous data, P values were calculated using the one-way ANOVA except in relation to
NT-proBNP, for which the Kruskal-Wallis test was used.
NR, not relevant; HC, healthy controls; CHF, chronic heart failure; CHD, coronary heart disease; HBP, hypertension; DCM, dilated cardiomyopathy; HR, heart rate;
SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left
ventricular end-systolic dimension; NT-proBNP, N-terminal probrain natriuretic peptide; eSOD, erythrocyte superoxide dismutase; MDA, malondialdehyde.
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increased in CHF patients.IL-33 levels and causes of CHF
To further explore whether different causes of CHF
affected the parameters evaluated, we performed a sub-
group analysis within the CHF group. Patients were
divided into four groups according to the pre-existing
cardiac disease causing CHF. The demographic data of
patients in the four groups are shown in Table 2. Age,
sex, echocardiographic data, and levels of NT-proBNP,
creatinine and oxidation markers were not significantly
different among the four groups. Results from the
Kruskal-Wallis test did not show a significant difference
in relation to serum levels of IL-33 or IL-33/sST2 ratios
among groups (Figures 4A and B).
We also examined whether consumption of different
medications upon hospital admission affected IL-33
levels. CHF patients were divided into five subgroups
according to medications used upon arrival at hospital,
and patients’ characteristics across different medication
groups were similar (data not shown). Serum levels ofIL-33 and IL-33/sST2 ratios were similar among dif-
ferent medical treatments upon hospital admission
(Figures 4C and D).Levels of IL-33, sST2, the IL-33/sST2 ratio and markers of
oxidation stress
IL-33 has been reported to reduce ROS production [8].
We performed Spearman’s correlation analyses to deter-
mine whether serum levels of IL-33 correlated with
eSOD activity and serum MDA content. Unexpectedly,
IL-33 levels were negatively correlated with eSOD ac-
tivity and positively related to serum MDA content
(Figures 5A and B). sST2 had a closer relationship with
these oxidation markers (Figures 5C and D). However,
IL-33/sST2 ratios were slightly (but significantly) neg-
atively correlated with serum MDA concentrations
(Figure 5E). Previous experimental studies have shown
that the anti-oxidation effects of IL-33 can be blocked
by co-administration with sST2. Hence, these data may
support the notion that the effects of IL-33 may be
overwhelmed by concurrently elevated levels of sST2 in
subjects with severe CHF.
Figure 1 Box chart for serum levels of IL-33 (A), sST2 (B), and IL-33/sST2 ratio (C). Circulating IL-33 and sST2 were significantly increased in
CHF patients whereas IL-33/sST2 ratios were decreased. Blood samples were obtained from healthy controls (HC, n = 177), cardiac-disease patients
without CHF (non-CHF patients, n =175) and CHF patients (CHF patients, n = 191). Data are expressed as minima, quartiles, and maxima. Statistical
analyses were done using the Kruskal-Wallis test followed by Dunn’s post-hoc test for multiple comparisons. The dotted line denotes the
sensitivity of the ELISA kits. Abbreviations are the same as those shown in Table 1.
Figure 2 Scatterplot between serum levels of IL-33 and NT-proBNP (A) and LVEF (B) in CHF patients. Serum levels of IL-33 were
significantly and positively correlated with those of NT-proBNP but negatively correlated with LVEF. Correlation coefficients were calculated by
Spearman’s correlation analyses. Abbreviations are the same as those shown in Table 1.
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Figure 3 Western blot analyses for serum in CHF patients,
non-CHF patients, and HC. IL-33 in serum was collected by
immunoprecipitation, which was subsequently subjected to western
blotting for analyzing the exact form of IL-33 in serum. Total IL-33
contents: 2.7 ng in CHF; 1.9 ng in non-CHF and 1.7 ng in HC.
c-IL33, cleaved IL-33; f-IL33, full-length IL-33. Other abbreviations are
the same as those shown in Table 1.
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To directly validate the antioxidative effects of in-
creased levels of IL-33 in human cardiomyocytes, we
assessed the effects of IL-33 in Ang II-stimulated AC16
cells and measured MDA content and SOD activity.Table 2 Demographic data of patients with different causes o
CHD HBP
n=103 n=39
Age (years) 66.30 ± 5.99 64.77 ± 6.31
Male (%) 63 (61.17%) 20 (51.28%)
HR (beat/min) 70.78 ± 16.89 73.26 ± 15.89
SBP (mmHg) 117.40 ± 21.09 149.71 ± 10.67
DBP (mmHg) 64.99 ± 14.36 84.69 ± 12.02
NYHA III/IV 43/60 13/26
Echocardiographic data
LVEF (%) 28.42 ± 4.04 27.48 ± 3.74
LVEDD (mm) 58.52 ± 6.40 59.53 ± 5.42
LVESD (mm) 37.53 ± 4.30 38.03 ± 3.94
Chemical markers
serum creatinine (μmol/l) 126.70 ± 80.40 133.17 ± 93.37
NT-proBNP (ρg/ml) 5281.94 (239.83-19199.74) 5029.96 (187.21-156
eSOD (U/mg Hb) 2.35 ± 1.10 2.22 ± 1.12
MDA (nmol/l) 4.90 ± 1.97 4.55 ± 1.93
Medications at arrival
ACEIs/ARBs (%) 25 (24.27) 9 (23.08)
βRB (%) 10 (9.71) 8 (20.51)
Statins (%) 28 (27.18) 1 (2.56)
Diuretics (%) 21 (20.29) 13 (33.33)
Digitalis (%) 25 (24.27) 12 (30.77)
Continuous data are the mean ± SD or median and range (for NT-proBNP). Categor
*For categorical data, P values were derived by Pearson’s χ2; for continuous data, P
Newman-Keuls test for multiple post-hoc comparisons except in relation to NT-proB
Association; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II rece
the same as shown in Table 1.IL-33 significantly increased SOD activity (Figure 6A)
and reduced MDA levels (Figure 6B) in a dose-
dependent manner. However, sST2 blocked these
effects to a great extent (Figures 6A and B). These data
suggested that sST2 could directly and considerably
inhibit the antioxidative effects of IL-33 in human
cardiomyocytes.Discussion
Since the discovery in 2005 that IL-33 as the natural lig-
and for ST2 [22], the IL-33/ST2 signalling pathway has
been a focus of scientific interest. Some animal studies
on this signalling pathway in CHF and cardiac fibrosis
have been carried out [8,12] but data detailing IL-33
levels in human CHF have not been reported. The
present study showed that serum levels of IL-33 were
elevated in CHF patients whereas IL-33/sST2 ratios were
significantly decreased, neither of which was associated
with CHF aetiologies. Serum levels of IL-33 were posi-
tively correlated with levels of markers of oxidative
stress, whereas the IL-33/sST2 ratio was associated withf CHF
CHD+HBP DCM P *
n = 35 n= 14
68.03 ± 5.51 66.93 ± 4.12 0.12
21 (60.00%) 5 (36%) 0.27
72.97 ± 16.92 77.5 ± 20.19 0.51
144.94 ± 12.19 100.86 ± 3.10 <0.01
79.23 ± 12.80 58.14 ± 6.86 <0.01
17/18 5/9 0.58
27.89 ± 4.11 28.47 ± 3.22 0.08
59.07 ± 5.82 61.32 ± 6.04 0.36
37.88 ± 4.14 38.48 ± 4.49 0.60
137.06 ± 82.00 135.70 ± 101.50 0.92
35.25) 6914.30 (687.84-15716.93) 5894.20 (1479.39-11550.13) 0.34
2.18 ± 1.24 2.04 ± 0.89 0.71
4.15 ± 2.06 4.85 ± 1.79 0.25
9 (25.71) 4 (28.57) 0.06
9 (17.14) 1 (7.14) 0.08
9 (25.71) 0 (0) <0.01
10 (28.57) 5 (35.71) 0.31
10 (28.57) 2 (14.29) 0.61
ical variables are presented as absolute and/or relative frequencies.
values were calculated using one-way ANOVA followed by the Student-
NP, for which the Kruskal-Wallis test was used. NYHA, New York Heart




Figure 4 Vertical bar chart for serum levels of IL-33 (A, C) and the IL-33/sST2 ratio (B, D) for various causes of CHF (A, B) and for
different medications (C, D). Serum samples were obtained from 103, 39, 35, and 14 patients with coronary heart disease, hypertension,
coronary heart disease and hypertension, and dilated cardiomyopathy, respectively. Data are expressed as quartiles and maxima. Serum levels of
IL-33 and IL-33/sST2 ratios were not significantly different among CHF patients with various causes (A, B). IL-33 levels and the IL-33/sST2 ratio in
patients under different drug therapies was similar (C, D). Statistical analyses were done using the Kruskal-Wallis test. The dotted line denotes the
sensitivity of the ELISA kits. Abbreviations are the same as those shown in Table 1.
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that expression of full-length IL-33 was up-regulated in
CHF patients. Moreover, we showed that IL-33 directly
reduced MDA content and increased SOD activity inAng II-stimulated AC16 cells, which however were over-
whelmed by the presence of sST2.
IL-33 has been demonstrated to be protective in CHF,
and the full-length form is thought to be more
Figure 5 Scatterplot between serum levels of IL-33 and eSOD activity (A) and MDA (B), serum levels of sST2 and eSOD activity (C) and
MDA (D), and between IL-33/sST2 ratios and MDA levels (E) in CHF patients. Serum levels of IL-33 were negatively correlated with eSOD
activity and positively correlated with serum MDA contents (A and B). sST2 had a closer relationship with these oxidation markers (C and D).
IL-33/sST2 ratios were slightly (but significantly) correlated with decreased MDA contents (E). Correlation coefficients were calculated by
Spearman’s correlation analyses. Abbreviations are the same as those shown in Tables 1 and 2.
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noteworthy was the suppression of NF-κB activity and
the reduction of ROS by IL-33. Therefore, one may
speculate that the significantly increased levels of the ac-
tive form of IL-33 in CHF patients may have protectiveeffects in the pathophysiological processes of CHF and
may reduce oxidative stress. However, IL-33 levels were
correlated with elevated levels of NT-proBNP, reduced
LVEF, and markers of oxidative stress in these patients,
which seemed to challenge the hypothesis of a protective
Figure 6 Recombinant human IL-33 dose-dependently reduced MDA contents (A, n = 6) and increased SOD activity (B, n = 6) in Ang II-
stimulated AC16 cells, which could be dramatically attenuated by sST2. Data are the mean ± SEM. All results were from three independent
sets. Statistical analyses were undertaken using one-way ANOVA with the Tukey post-hoc test for multiple comparisons. The paired t-test was
used to compare values for samples with and without sST2 (10 μg/ml). *, P< 0.05 versus Ang II+PBS; }, P< 0.01 versus 1 ng/ml IL-33; }, P< 0.05
versus 5 ng/ml IL-33; {, P< 0.05 versus 10 ng/ml IL-33. Abbreviations are the same as those shown in Table 1.
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for these contradictory data may be that, as suggested in
a previous study, the effects of IL-33 were blocked by
concurrently elevated levels of sST2, which may serve as
a decoy receptor and inhibit IL-33 bioactivity. Thus, the
increased concentrations of IL-33 in CHF patients, des-
pite being positively correlated with CHF severity and
markers of oxidative stress, may have a compensatory
role, which was limited due to the elevated levels of
sST2. As a result, the elevation of IL-33 levels in CHF
might only reflect disease severity and the extent of oxi-
dative stress. The positive correlations between IL-33
levels and markers of oxidative stress may also be a re-
sult of inhibited bioactivity by sST2. This leads to an in-
ability to decreased reduction of ROS [8] and
subsequent oxidative stress. Notably, as suggested by
other authors, the role of sST2 as a reservoir for IL-33
and increasing the circulation half-life of IL-33 (which
has been found in the IL-6 receptor) cannot be ruled out
[8,24].
In contrast to our findings, Dhillon and colleagues
reported that IL-33 levels were not correlated with ad-
verse outcomes in non-ST-elevation myocardial infarc-
tion (NSTEMI) patients [25]. Two phenomena may
explain these conflicting findings. Firstly, the study by
Dhillon et al. focused on the predicted value of IL-33
in NSTEMI patients, whereas the present study con-
centrated on the difference in IL-33 levels between
CHF patients and non-CHF subjects. All the partici-
pants in the study by Dhillon et al. were NSTEMI
patients, and comparisons between patients and healthy
individuals were not made. Secondly, the studied popu-
lation between the two studies was different. Fewpatients (13 of 577; 2.25%) suffered from pre-existing
heart failure and only a few patients had heart failure
(52 of 577; 9%) during the studying period in the study
by Dhillon et al., whereas patients with acute myocar-
dial infarction were excluded in our study. Therefore,
the main diseases affecting serum levels of IL-33 in the
previous study may have been myocardial infarction,
whereas the main disease affecting serum IL-33 levels
in the present study was severe systolic CHF. In
addition, the mean value of LVEF in patients of the
study by Dhillon et al. was much higher than that in
the present study [25]. Therefore, the distinct charac-
teristics of patients in the two studies may be an im-
portant reason for the different results. Interestingly, in
the present study, IL-33 levels were positively corre-
lated with NT-proBNP levels, a strong predictor for ad-
verse outcome, which might indicate a role for IL-33 in
predicting the adverse outcomes of CHF. IL-33 is not
associated with poor outcome in NSTEMI patients
[25], so the predictive value of IL-33 in CHF remains
elusive.
The potential sources for the increased levels of IL-33
are unknown, and the release of full-length IL-33 is
controversial [26,27]. Some researchers have reported
elevated levels of IL-33 in serum and speculated that
some cells (e.g., fibroblasts, endothelial cells, macro-
phages) may be the potential sources [28-30]. One
study showed that IL-33 expression in cardiac fibro-
blasts was up-regulated upon mechanical strain [8]. Im-
portantly, increased IL-33 contents were found in the
supernatants of stimulated cardiac fibroblasts, which
suggested that IL-33 could be secreted by cardiac
fibroblasts [8]. Very recently, Lee and colleagues
Zhang et al. Journal of Translational Medicine 2012, 10:120 Page 10 of 11
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directly by living fibroblasts upon biomechanical over-
load, which was noted in both mouse fibroblasts cell
lines and human primary skin fibroblasts [31]. There-
fore, one may speculate that mechanical stress in cardiac
fibroblasts in CHF may be responsible (at least in part)
for the elevated circulating levels of IL-33. In addition,
endothelial cells have been shown to abundantly express
IL-33 and increased endothelial damage has been found
in CHF patients [32]. Thus, full-length IL-33 from the
damaged endothelium may also contribute to the ele-
vated serum levels of IL-33 observed in the present
study. Even though studies have shown that cellular ex-
pression of IL-33 is increased upon stimulation [8], we
found that IL-33 was scarcely detected in the superna-
tants of PMA-stimulated AC16 cells, whereas signifi-
cantly increased levels of IL-33 could be found in cell
lysates (data not shown). Thus, release of IL-33 from
cardiomyocytes should be demonstrated in further stud-
ies, and more studies may be needed to explore the po-
tential sources of IL-33 in CHF.
Some limitations of the current study should be noted.
Firstly, all CHF patients recruited in the present study
had advanced systolic CHF. Therefore, the importance
of altered IL-33 levels in other CHF patients, especially
in those with preserved ejection fraction, who have been
demonstrated to have lower sST2 levels compared with
those with systolic CHF [33], are not clear. Given the
similar biomechanically induced secretion mechanisms
shared by sST2 and IL-33 [8], one could hypothesize
that IL-33 levels in CHF patients with preserved ejection
fraction may be different. Secondly, all patients in-
cluded in the present study were treated with anti-CHF
therapies (e.g., β-receptor blockers, diuretics, angiotensin-
converting enzyme inhibitors and angiotensin-II recep-
tor blockers). Therefore, it may be difficult to compare
our patients with other CHF patients who did not re-
ceive similar medications. Thirdly, as mentioned above, we
did not explore the predictive value of IL-33 levels in
CHF. Finally, even though some studies have used the
IL-33/sST2 ratio to reflect IL-33 bioactivity, a change in
the ratio might simply reflect differences in the mechan-
isms of induction of IL-33 and sST2, and may not neces-
sarily be an indicator of IL-33 activity.
Conclusions
The present study revealed significantly up-regulated cir-
culating levels of IL-33 (especially the full-length form),
but decreased IL-33/sST2 ratios in CHF patients. The
IL-33/sST2 ratio was negatively correlated to oxidation
in CHF patients. IL-33 directly attenuated oxidative
stress, which was blocked by sST2. More studies are
required to confirm these findings in CHF patients with
preserved ejection fraction.Abbreviations
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